An HSP90 Inhibitor, PU-H71, Antagonizes Stroma-Induced Pro-Survival Effects in CLL through Its Inhibition of Multi-Component B-Cell Receptor Signaling Pathway
Background: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B-cells in the hematopoietic system. The B-cell receptor (BCR) plays an essential role in the pathogenesis of CLL and many components of the BCR signaling pathway are known clients of HSP90. HSP90 is a highly cons...
Saved in:
Published in | Blood Vol. 126; no. 23; p. 5289 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
03.12.2015
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B-cells in the hematopoietic system. The B-cell receptor (BCR) plays an essential role in the pathogenesis of CLL and many components of the BCR signaling pathway are known clients of HSP90. HSP90 is a highly conserved molecular chaperone that ensures the proper folding and stabilization of its client proteins. In this study, we investigated whether PU-H71 a novel purine-scaffold HSP90 Inhibitor, has anti-tumor activity in CLL by destabilizing BCR signaling pathway constituents.
Design: Fresh CLL cells were isolated and cultured ex vivo with or without stromal co-culture. Molecular and cellular events were studied in PU-H71-treated and control CLL cells.
Results: Immunoblotting revealed that a significantly higher amount of HSP90 is present in CLL cells than in peripheral blood mononuclear cells (PBMC), suggesting the chaperone is pathogenically relevant. We found that PU-H71 caused the death of CLL cells in a dose and time dependent manner while the viability of either PBMC or normal B lymphocytes were not affected. PU-H71 induced apoptosis resulting in CLL cell death as it caused mitochondrial cytochrome C release and a decrease in the abundance of several anti-apoptotic proteins. Interestingly, PU-H71 has the ability to counteract the pro-survival effects of the stroma and caused apoptosis in CLL cells co-cultured with stroma. To gain mechanistic insights into how PU-H71 acts, we examined the BCR signaling pathway. We found that the amounts of several key components of the pathway were reduced by PU-H71 treatment. This occurred even in the presence of stromal co-culture. The results suggest that PU-H71 antagonizes the function of HSP90 leading to the destabilization of the BCR signaling transducers. A chemical pull-down experiment revealed the co-existence of the BCR components and HSP90 in the same complex, suggesting these BCR constituents are indeed clients of HSP90 in CLL cells. Further, specific genetic knock-down of the signal transducers by siRNA confirmed their key roles in mediating the survival of CLL cells.
Conclusions: PU-H71 antagonizes stroma-induced pro-survival effects in CLL through its inhibition of the B-cell receptor signaling pathway. Our results suggest that PU-H71 may serve as a useful therapy against CLL and is worth further clinical development.
No relevant conflicts of interest to declare. |
---|---|
AbstractList | Abstract
Background: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B-cells in the hematopoietic system. The B-cell receptor (BCR) plays an essential role in the pathogenesis of CLL and many components of the BCR signaling pathway are known clients of HSP90. HSP90 is a highly conserved molecular chaperone that ensures the proper folding and stabilization of its client proteins. In this study, we investigated whether PU-H71 a novel purine-scaffold HSP90 Inhibitor, has anti-tumor activity in CLL by destabilizing BCR signaling pathway constituents.
Design: Fresh CLL cells were isolated and cultured ex vivo with or without stromal co-culture. Molecular and cellular events were studied in PU-H71-treated and control CLL cells.
Results: Immunoblotting revealed that a significantly higher amount of HSP90 is present in CLL cells than in peripheral blood mononuclear cells (PBMC), suggesting the chaperone is pathogenically relevant. We found that PU-H71 caused the death of CLL cells in a dose and time dependent manner while the viability of either PBMC or normal B lymphocytes were not affected. PU-H71 induced apoptosis resulting in CLL cell death as it caused mitochondrial cytochrome C release and a decrease in the abundance of several anti-apoptotic proteins. Interestingly, PU-H71 has the ability to counteract the pro-survival effects of the stroma and caused apoptosis in CLL cells co-cultured with stroma. To gain mechanistic insights into how PU-H71 acts, we examined the BCR signaling pathway. We found that the amounts of several key components of the pathway were reduced by PU-H71 treatment. This occurred even in the presence of stromal co-culture. The results suggest that PU-H71 antagonizes the function of HSP90 leading to the destabilization of the BCR signaling transducers. A chemical pull-down experiment revealed the co-existence of the BCR components and HSP90 in the same complex, suggesting these BCR constituents are indeed clients of HSP90 in CLL cells. Further, specific genetic knock-down of the signal transducers by siRNA confirmed their key roles in mediating the survival of CLL cells.
Conclusions: PU-H71 antagonizes stroma-induced pro-survival effects in CLL through its inhibition of the B-cell receptor signaling pathway. Our results suggest that PU-H71 may serve as a useful therapy against CLL and is worth further clinical development.
Disclosures
No relevant conflicts of interest to declare. Background: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B-cells in the hematopoietic system. The B-cell receptor (BCR) plays an essential role in the pathogenesis of CLL and many components of the BCR signaling pathway are known clients of HSP90. HSP90 is a highly conserved molecular chaperone that ensures the proper folding and stabilization of its client proteins. In this study, we investigated whether PU-H71 a novel purine-scaffold HSP90 Inhibitor, has anti-tumor activity in CLL by destabilizing BCR signaling pathway constituents. Design: Fresh CLL cells were isolated and cultured ex vivo with or without stromal co-culture. Molecular and cellular events were studied in PU-H71-treated and control CLL cells. Results: Immunoblotting revealed that a significantly higher amount of HSP90 is present in CLL cells than in peripheral blood mononuclear cells (PBMC), suggesting the chaperone is pathogenically relevant. We found that PU-H71 caused the death of CLL cells in a dose and time dependent manner while the viability of either PBMC or normal B lymphocytes were not affected. PU-H71 induced apoptosis resulting in CLL cell death as it caused mitochondrial cytochrome C release and a decrease in the abundance of several anti-apoptotic proteins. Interestingly, PU-H71 has the ability to counteract the pro-survival effects of the stroma and caused apoptosis in CLL cells co-cultured with stroma. To gain mechanistic insights into how PU-H71 acts, we examined the BCR signaling pathway. We found that the amounts of several key components of the pathway were reduced by PU-H71 treatment. This occurred even in the presence of stromal co-culture. The results suggest that PU-H71 antagonizes the function of HSP90 leading to the destabilization of the BCR signaling transducers. A chemical pull-down experiment revealed the co-existence of the BCR components and HSP90 in the same complex, suggesting these BCR constituents are indeed clients of HSP90 in CLL cells. Further, specific genetic knock-down of the signal transducers by siRNA confirmed their key roles in mediating the survival of CLL cells. Conclusions: PU-H71 antagonizes stroma-induced pro-survival effects in CLL through its inhibition of the B-cell receptor signaling pathway. Our results suggest that PU-H71 may serve as a useful therapy against CLL and is worth further clinical development. No relevant conflicts of interest to declare. |
Author | Zhen, Chaojie Lu, Pin Chiosis, Gabriela Wang, Yue Lynn Guo, Ailin |
Author_xml | – sequence: 1 givenname: Ailin surname: Guo fullname: Guo, Ailin organization: Division of Genomic and Molecular Pathology, Department of Pathology, University of Chicago, Chicago, IL – sequence: 2 givenname: Pin surname: Lu fullname: Lu, Pin organization: Division of Genomic and Molecular Pathology, Department of Pathology, University of Chicago, Chicago, IL – sequence: 3 givenname: Chaojie surname: Zhen fullname: Zhen, Chaojie organization: Division of Genomic and Molecular Pathology, Department of Pathology, University of Chicago, Chicago, IL – sequence: 4 givenname: Gabriela surname: Chiosis fullname: Chiosis, Gabriela organization: Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY – sequence: 5 givenname: Yue Lynn surname: Wang fullname: Wang, Yue Lynn organization: Division of Genomic and Molecular Pathology, Department of Pathology, University of Chicago, Chicago, IL |
BookMark | eNqFkN1OAjEQhRujifjzDM4DWOzPbule4kaFBCMR9bYp2xZqlpZ0Fww-jM_qAt57c04yyTkz812g0xCDReiGkj6lkt3N6xhN_4My0We8nzNZHOQE9WjnmBBGTlGPECJwVgzoObpomk9CaMZZ3kM_wwCj2bQgMA5LP_dtTLcwfcejAb2FYWj1Igb_bRuYtSmuNB4Hs6msgWmKeLZJW7_VNTw4Z6u2AR-gnEygXaa4WSxh3I3-Wn0MEB08b-rW4zKu1t0PoYV7XNq6hldb2XW3GWZ-EXTtwwKmul1-6d0VOnO6buz1n1-it8eHt3KEJy9P43I4wRUlosCcGcYq7awxTIiMayY1qwhxgma6KDiXUgtNnSM5zy2T1nAhcpsZImUmBb9Eg2NtlWLTJOvUOvmVTjtFidpTVgfKak9ZMa72gA_SJYfHpO2u23qbVFN5GzpEPnVMlIn-345f8sOJsg |
ContentType | Journal Article |
Copyright | 2015 American Society of Hematology |
Copyright_xml | – notice: 2015 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood.V126.23.5289.5289 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 5289 |
ExternalDocumentID | 10_1182_blood_V126_23_5289_5289 S0006497118522795 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI AAYXX ADVLN AITUG AKRWK AMRAJ CITATION H13 |
ID | FETCH-LOGICAL-c1069-32d22cafedd26643a28a2c00f614a993388a6a1ff0535e28ed3665e4d0884863 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Fri Aug 23 01:16:33 EDT 2024 Fri Feb 23 02:42:58 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 23 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1069-32d22cafedd26643a28a2c00f614a993388a6a1ff0535e28ed3665e4d0884863 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497118522795 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_V126_23_5289_5289 elsevier_sciencedirect_doi_10_1182_blood_V126_23_5289_5289 |
PublicationCentury | 2000 |
PublicationDate | 2015-12-03 |
PublicationDateYYYYMMDD | 2015-12-03 |
PublicationDate_xml | – month: 12 year: 2015 text: 2015-12-03 day: 03 |
PublicationDecade | 2010 |
PublicationTitle | Blood |
PublicationYear | 2015 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 2.2102137 |
Snippet | Background: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B-cells in the hematopoietic system. The B-cell receptor (BCR) plays an... Abstract Background: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B-cells in the hematopoietic system. The B-cell receptor (BCR)... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 5289 |
Title | An HSP90 Inhibitor, PU-H71, Antagonizes Stroma-Induced Pro-Survival Effects in CLL through Its Inhibition of Multi-Component B-Cell Receptor Signaling Pathway |
URI | https://dx.doi.org/10.1182/blood.V126.23.5289.5289 |
Volume | 126 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7SDX1cSrtpadI2zKH0FO3akp-9eU3DbrMpC5uE3Ixsy6kh0S6bDSH9Mf2tHclyaaHQQy_GCGQLjTzfN54XwIeEUK9UsWAlb2xR7ZQltVCsrsn2IE0ZCOvRPf0aTc-DL5fh5Q7kfS6MCat0ur_T6VZbu5Gx283xum1Nji_BaRr7Jv2Xx2n4CHZ5HHl8ALvZ5OJk_suZEAjeNTIg49lMcGFexKzHNjp8dOHzaMTFKCTrw17-DlK_Ac_xC3juGCNm3aJewo7SQ9jLNFnLNw_4EW0Mp_05PoTHk_7uad53chvCk1PnQN-DH5nG6XKRejjT39qSPufNES7O2TT2jzDTxkWl2-_qFpfbzepGMtPZg_YIF5sVW96RWqGDiV3F41tsNebzObpWPzijIfdUEjauGrTZvcyonJUmcMMJy9X1NRJVVWt6My7bK2MH6CtcEBG9lw-v4Oz481k-Za5FA6vIlkyZ4DXnlWxUXRPSB0LyRPLK8xpCfUnURySJjKTfNKaMjOKJqkUUhSqoSbkFdE5ew0DTCt4ApkL5ppSM0SpBoqq0Cr0yUnFVRrKSKt0HrxdJse4KcRTWgEl4YaVYGCkWXBRGgPayD5960RV_nKmC4OJfkw_-Z_JbeEbEKrRhL-IdDLabO_WeyMu2PHSH85Do--zkJ3DG6iE |
link.rule.ids | 315,786,790,27602,27957,27958,45698 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLdGJxgXBB1oGwPeAXGa28TO525pxJSydKrUbtotchJnRNrcquuExh_D38qz4yCQkDhwiSJLTiw_5_1-L--LkI8Rol4pQ05L1pii2jGNai5pXaPtgZrS48ajO7sIskvvy7V_vUPSPhdGh1Va3d_pdKOt7cjY7uZ43bY6xxfhNA5dnf7Lwth_QnaRDcTRgOwmk6vz_JczweOsa2SAxrOeYMO8kFmPTXT46MplwYjxkY_Wh7n8HaR-A56zl-SFZYyQdIt6RXakGpL9RKG1fPcIn8DEcJqf40PydNLf7aV9J7cheTazDvR98iNRkC3msQNT9bUt8XPenMD8kmahewKJ0i4q1X6X97DYblZ3gurOHrhHMN-s6OIB1QoeTOgqHt9DqyDNc7CtfmCKQ_apKGxYNWCye6lWOSuF4AYTmsrbW0CqKtf4Zli0N9oOUDcwRyL6TTy-Jsuzz8s0o7ZFA63QlowpZzVjlWhkXSPSe1ywSLDKcRpEfYHUh0eRCITbNLqMjGSRrHkQ-NKrUbl5eE7ekIHCFRwQiLl0dSkZrVW8SFZx5TtlIMOqDEQlZHxInF4kxborxFEYAyZihZFioaVYMF5oAZrLITntRVf8caYKhIt_TT76n8kfyF62nOVFPr04f0ueI8nyTQgMPyaD7eZBvkMisy3f24P6Ey3W7CE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+HSP90+Inhibitor%2C+PU-H71%2C+Antagonizes+Stroma-Induced+Pro-Survival+Effects+in+CLL+through+Its+Inhibition+of+Multi-Component+B-Cell+Receptor+Signaling+Pathway&rft.jtitle=Blood&rft.au=Guo%2C+Ailin&rft.au=Lu%2C+Pin&rft.au=Zhen%2C+Chaojie&rft.au=Chiosis%2C+Gabriela&rft.date=2015-12-03&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=126&rft.issue=23&rft.spage=5289&rft.epage=5289&rft_id=info:doi/10.1182%2Fblood.V126.23.5289.5289&rft.externalDocID=S0006497118522795 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |